Safrazine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Safrazine
Accession Number
DB09253
Type
Small Molecule
Groups
Withdrawn
Description

Safrazine (Safra) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was introduced as an antidepressant in the 1960s, but has since been discontinued.

Structure
Thumb
Synonyms
  • Safra
Categories
UNII
F5G0P5378C
CAS number
33419-68-0
Weight
Average: 208.261
Monoisotopic: 208.121177763
Chemical Formula
C11H16N2O2
InChI Key
IBWPUTAKVGZXRB-UHFFFAOYSA-N
InChI
InChI=1S/C11H16N2O2/c1-8(13-12)2-3-9-4-5-10-11(6-9)15-7-14-10/h4-6,8,13H,2-3,7,12H2,1H3
IUPAC Name
[4-(2H-1,3-benzodioxol-5-yl)butan-2-yl]hydrazine
SMILES
CC(CCC1=CC2=C(OCO2)C=C1)NN

Pharmacology

Indication

For the treatment of depression.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Safrazine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Safrazine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Safrazine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Safrazine.Experimental, Illicit
4-MethoxyamphetamineSafrazine may increase the hypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Safrazine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineSafrazine may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbediterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Abediterol.Investigational
AcarboseSafrazine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololSafrazine may increase the hypotensive activities of Acebutolol.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Safrazine.Experimental
AlbiglutideSafrazine may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Safrazine.Approved, Illicit
AliskirenSafrazine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Safrazine.Approved, Investigational
AlogliptinSafrazine may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Safrazine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Safrazine.Illicit
AlprenololSafrazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Safrazine.Approved
AmbrisentanSafrazine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineSafrazine may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylineSafrazine may increase the serotonergic activities of Amitriptyline.Approved
AmitriptylinoxideSafrazine may increase the serotonergic activities of Amitriptylinoxide.Approved, Investigational
AmlodipineSafrazine may increase the hypotensive activities of Amlodipine.Approved
AmoxapineSafrazine may increase the serotonergic activities of Amoxapine.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Safrazine.Approved, Illicit, Investigational
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Safrazine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Safrazine is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Safrazine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Arformoterol.Approved, Investigational
AtenololSafrazine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineSafrazine may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineSafrazine may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Bambuterol.Approved, Investigational
BenazeprilSafrazine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideSafrazine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypertensive activities of Safrazine.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Safrazine.Approved, Illicit
BepridilSafrazine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Safrazine.Approved, Investigational
BetaxololSafrazine may increase the hypotensive activities of Betaxolol.Approved, Investigational
BethanidineSafrazine may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Safrazine is combined with Bezafibrate.Approved, Investigational
BietaserpineSafrazine may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostSafrazine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololSafrazine may increase the hypotensive activities of Bisoprolol.Approved
BitolterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Bitolterol.Withdrawn
BosentanSafrazine may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Safrazine may increase the hypotensive activities of BQ-123.Investigational
BretyliumSafrazine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe metabolism of Brexpiprazole can be decreased when combined with Safrazine.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Safrazine is combined with Brimonidine.Approved
BrofaromineSafrazine may increase the hypertensive activities of Brofaromine.Experimental
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Safrazine.Approved, Investigational
BupranololSafrazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Safrazine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Safrazine is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Safrazine is combined with Buspirone.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Safrazine.Approved, Illicit, Vet Approved
ButriptylineSafrazine may increase the serotonergic activities of Butriptyline.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Safrazine.Approved
CadralazineSafrazine may increase the hypotensive activities of Cadralazine.Experimental
CafedrineSafrazine may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinSafrazine may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanSafrazine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilSafrazine may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilSafrazine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilSafrazine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Safrazine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Safrazine.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Safrazine.Approved, Investigational
CaroxazoneSafrazine may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololSafrazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolSafrazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololSafrazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideSafrazine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Safrazine.Illicit, Withdrawn
ChlorpropamideSafrazine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneSafrazine may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineSafrazine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilSafrazine may increase the hypotensive activities of Cilazapril.Approved
CinitaprideThe metabolism of Cinitapride can be decreased when combined with Safrazine.Approved, Investigational
CirazolineSafrazine may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Safrazine.Approved
ClemastineSafrazine may increase the anticholinergic activities of Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineSafrazine may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
ClonidineSafrazine may increase the hypertensive activities of Clonidine.Approved
CloranololSafrazine may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Safrazine.Approved, Illicit
CryptenamineSafrazine may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Safrazine.Approved
CyclopenthiazideSafrazine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideSafrazine may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineSafrazine may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinSafrazine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Safrazine.Investigational
DebrisoquinSafrazine may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilSafrazine may increase the hypotensive activities of Delapril.Experimental
DeserpidineSafrazine may increase the hypotensive activities of Deserpidine.Approved
DesipramineSafrazine may increase the serotonergic activities of Desipramine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Safrazine.Approved, Investigational
DeutetrabenazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Deutetrabenazine.Approved, Investigational
DexmethylphenidateSafrazine may increase the hypertensive activities of Dexmethylphenidate.Approved, Investigational
DextroamphetamineThe risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Safrazine.Approved, Illicit
DextromethorphanSafrazine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Safrazine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Safrazine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Safrazine.Approved, Investigational
DiazoxideSafrazine may increase the hypotensive activities of Diazoxide.Approved
DibenzepinSafrazine may increase the serotonergic activities of Dibenzepin.Experimental
DiethylnorspermineSafrazine may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylpropionSafrazine may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineSafrazine may increase the hypotensive activities of Dihydralazine.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Safrazine.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Safrazine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Safrazine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Safrazine.Experimental, Illicit
DiltiazemSafrazine may increase the hypotensive activities of Diltiazem.Approved, Investigational
DimetacrineSafrazine may increase the serotonergic activities of Dimetacrine.Approved, Withdrawn
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Safrazine.Approved, Illicit
DipivefrinSafrazine may increase the hypertensive activities of Dipivefrin.Approved
DisopyramideSafrazine may increase the hypoglycemic activities of Disopyramide.Approved
DisulfiramThe risk or severity of convulsion can be increased when Safrazine is combined with Disulfiram.Approved
DobutamineThe risk or severity of adverse effects can be increased when Safrazine is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Safrazine is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideSafrazine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinSafrazine may increase the serotonergic activities of Dosulepin.Approved
DoxapramSafrazine may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinSafrazine may increase the hypotensive activities of Doxazosin.Approved
DoxepinSafrazine may increase the serotonergic activities of Doxepin.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Safrazine is combined with Doxofylline.Approved, Investigational
DoxylamineSafrazine may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Safrazine.Experimental
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Safrazine.Experimental, Illicit
DroxidopaSafrazine may increase the hypertensive activities of Droxidopa.Approved, Investigational
DulaglutideSafrazine may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Safrazine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Safrazine.Experimental, Illicit
EfonidipineSafrazine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Safrazine.Approved, Investigational
EmpagliflozinSafrazine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilSafrazine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatSafrazine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineSafrazine may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Safrazine.Approved, Investigational
EpanololSafrazine may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Safrazine is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineSafrazine may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolSafrazine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanSafrazine may increase the hypotensive activities of Eprosartan.Approved
ErgonovineSafrazine may increase the hypertensive activities of Ergonovine.Approved
ErgotamineSafrazine may increase the hypertensive activities of Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Safrazine.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Safrazine is combined with Etafedrine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Safrazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Safrazine.Approved, Illicit
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Safrazine.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Safrazine.Illicit, Vet Approved
ExenatideSafrazine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineSafrazine may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineSafrazine may increase the serotonergic activities of Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoldopamSafrazine may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Safrazine.Approved, Illicit, Investigational, Vet Approved
Ferulic acidSafrazine may increase the hypotensive activities of Ferulic acid.Experimental
FlibanserinThe metabolism of Flibanserin can be decreased when combined with Safrazine.Approved, Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Safrazine.Approved, Vet Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Safrazine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Formoterol.Approved, Investigational
FosinoprilSafrazine may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe serum concentration of Frovatriptan can be increased when it is combined with Safrazine.Approved, Investigational
FurazolidoneSafrazine may increase the hypertensive activities of Furazolidone.Approved, Investigational, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Safrazine.Experimental
GliclazideSafrazine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideSafrazine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideSafrazine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideSafrazine may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzSafrazine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelSafrazine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineSafrazine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineSafrazine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineSafrazine may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorSafrazine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzSafrazine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanSafrazine may increase the hypotensive activities of Guanoxan.Experimental
HarmalineSafrazine may increase the hypertensive activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Safrazine.Approved, Illicit, Investigational
HexamethoniumSafrazine may increase the hypotensive activities of Hexamethonium.Experimental
HexoprenalineThe risk or severity of adverse effects can be increased when Safrazine is combined with Hexoprenaline.Approved, Withdrawn
HydracarbazineHydracarbazine may increase the hypertensive activities of Safrazine.Experimental
HydralazineSafrazine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideSafrazine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Safrazine.Approved, Illicit
HydroflumethiazideSafrazine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Safrazine.Approved, Illicit
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Safrazine.Approved
ImidaprilSafrazine may increase the hypotensive activities of Imidapril.Investigational
ImipramineSafrazine may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Indalpine is combined with Safrazine.Investigational, Withdrawn
IndapamideSafrazine may increase the hypotensive activities of Indapamide.Approved
IndenololSafrazine may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminSafrazine may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartSafrazine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirSafrazine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineSafrazine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineSafrazine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanSafrazine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproSafrazine may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Safrazine.Approved
IprindoleSafrazine may increase the serotonergic activities of Iprindole.Experimental
IproclozideIproclozide may increase the hypertensive activities of Safrazine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Safrazine.Withdrawn
IrbesartanSafrazine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Safrazine.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Safrazine is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Safrazine is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Safrazine is combined with Isoprenaline.Approved, Investigational
IsradipineSafrazine may increase the hypotensive activities of Isradipine.Approved, Investigational
KetanserinSafrazine may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Safrazine.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Safrazine.Approved, Nutraceutical, Withdrawn
LabetalolSafrazine may increase the hypotensive activities of Labetalol.Approved
LacidipineSafrazine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostSafrazine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineSafrazine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Safrazine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Safrazine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Safrazine.Approved, Investigational
LevonordefrinSafrazine may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Safrazine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Safrazine is combined with Levosalbutamol.Approved, Investigational
LinezolidThe risk or severity of adverse effects can be increased when Safrazine is combined with Linezolid.Approved, Investigational
LinsidomineSafrazine may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideSafrazine may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Safrazine.Approved, Investigational
LisinoprilSafrazine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Safrazine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Safrazine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Safrazine.Illicit
LofepramineSafrazine may increase the serotonergic activities of Lofepramine.Experimental
LofexidineThe metabolism of Lofexidine can be decreased when combined with Safrazine.Approved, Investigational
LorpiprazoleThe risk or severity of serotonin syndrome can be increased when Lorpiprazole is combined with Safrazine.Approved
LosartanSafrazine may increase the hypotensive activities of Losartan.Approved
MacitentanSafrazine may increase the hypotensive activities of Macitentan.Approved
ManidipineSafrazine may increase the hypotensive activities of Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Safrazine is combined with Maprotiline.Approved, Investigational
MebanazineMebanazine may increase the hypertensive activities of Safrazine.Withdrawn
MecamylamineSafrazine may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MecaserminSafrazine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MelitracenSafrazine may increase the serotonergic activities of Melitracen.Experimental, Investigational
MephedroneThe risk or severity of adverse effects can be increased when Mephedrone is combined with Safrazine.Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Safrazine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Safrazine.Experimental
MequitazineSafrazine may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolSafrazine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminSafrazine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Safrazine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Safrazine.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Safrazine.Approved, Illicit
MethoserpidineSafrazine may increase the hypotensive activities of Methoserpidine.Experimental
MethoxamineSafrazine may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Safrazine.Experimental
MethyldopaThe risk or severity of hypertension can be increased when Safrazine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Safrazine.Experimental
Methylene blueSafrazine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateSafrazine may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethysergideThe metabolism of Methysergide can be decreased when combined with Safrazine.Approved
MetipranololSafrazine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneSafrazine may increase the hypotensive activities of Metolazone.Approved
MetoprololSafrazine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineSafrazine may increase the hypotensive activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Safrazine is combined with Mianserin.Approved, Investigational
MibefradilSafrazine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineSafrazine may increase the hypertensive activities of Midodrine.Approved
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Safrazine.Experimental, Illicit, Investigational
MifepristoneSafrazine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolSafrazine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Safrazine.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of Safrazine.Approved
MinoxidilSafrazine may increase the hypotensive activities of Minoxidil.Approved, Investigational
MirtazapineThe risk or severity of adverse effects can be increased when Safrazine is combined with Mirtazapine.Approved
MMDAThe risk or severity of adverse effects can be increased when MMDA is combined with Safrazine.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Safrazine is combined with Moclobemide.Approved, Investigational
MoexiprilSafrazine may increase the hypotensive activities of Moexipril.Approved
MorphineThe therapeutic efficacy of Morphine can be increased when used in combination with Safrazine.Approved, Investigational
MoxonidineSafrazine may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineSafrazine may increase the hypotensive activities of Muzolimine.Experimental
NadololSafrazine may increase the hypotensive activities of Nadolol.Approved
NaftopidilSafrazine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Safrazine.Approved
NaluzotanThe metabolism of Naluzotan can be decreased when combined with Safrazine.Investigational
NaphazolineSafrazine may increase the hypertensive activities of Naphazoline.Approved
NaratriptanThe serum concentration of Naratriptan can be increased when it is combined with Safrazine.Approved, Investigational
NateglinideSafrazine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololSafrazine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Safrazine.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Safrazine.Withdrawn
NicardipineSafrazine may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicorandilSafrazine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineSafrazine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineSafrazine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineSafrazine may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineSafrazine may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineSafrazine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideSafrazine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NorepinephrineSafrazine may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Safrazine.Approved, Illicit
NortriptylineSafrazine may increase the serotonergic activities of Nortriptyline.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Safrazine.Withdrawn
OlanzapineSafrazine may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlmesartanSafrazine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Olodaterol.Approved
OmapatrilatSafrazine may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolSafrazine may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Safrazine.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Safrazine is combined with Orciprenaline.Approved
OxprenololSafrazine may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Safrazine is combined with Oxycodone.Approved, Illicit, Investigational
OxymetazolineSafrazine may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Safrazine.Approved, Investigational, Vet Approved
PargylinePargyline may increase the hypertensive activities of Safrazine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Safrazine.Approved, Investigational
PenbutololSafrazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineSafrazine may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Safrazine.Approved, Vet Approved
PentoliniumSafrazine may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Safrazine.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilSafrazine may increase the hypotensive activities of Perindopril.Approved
PethidineSafrazine may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PF-00610355The risk or severity of adverse effects can be increased when Safrazine is combined with PF-00610355.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Safrazine.Experimental
PhendimetrazineSafrazine may increase the hypertensive activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the hypertensive activities of Safrazine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Safrazine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Safrazine.Experimental
PhenoxybenzamineSafrazine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Safrazine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Safrazine.Approved, Illicit
PhentolamineSafrazine may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineSafrazine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Safrazine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Safrazine.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Safrazine.Investigational
PinacidilSafrazine may increase the hypotensive activities of Pinacidil.Approved
PindololSafrazine may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneSafrazine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Safrazine.Approved, Investigational
PirlindolePirlindole may increase the hypertensive activities of Safrazine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Safrazine.Withdrawn
PizotifenSafrazine may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorSafrazine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideSafrazine may increase the hypotensive activities of Polythiazide.Approved
PramlintideSafrazine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinSafrazine may increase the hypotensive activities of Prazosin.Approved
ProcaineSafrazine may increase the hypertensive activities of Procaine.Approved, Investigational, Vet Approved
ProcarbazineSafrazine may increase the hypertensive activities of Procarbazine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Procaterol.Approved, Investigational
PropranololSafrazine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Safrazine is combined with Protokylol.Approved, Vet Approved
ProtriptylineSafrazine may increase the serotonergic activities of Protriptyline.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Safrazine.Approved
QuinaprilSafrazine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineSafrazine may increase the hypoglycemic activities of Quinine.Approved
RacepinephrineSafrazine may increase the hypertensive activities of Racepinephrine.Approved
RamiprilSafrazine may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Safrazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Safrazine.Approved
RemikirenSafrazine may increase the hypotensive activities of Remikiren.Approved
RepaglinideSafrazine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineSafrazine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Safrazine is combined with Reserpine.Approved, Investigational
RilmenidineSafrazine may increase the hypotensive activities of Rilmenidine.Approved, Investigational
RiociguatSafrazine may increase the hypotensive activities of Riociguat.Approved
RitobegronThe risk or severity of adverse effects can be increased when Ritobegron is combined with Safrazine.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Safrazine is combined with Ritodrine.Approved, Investigational
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Safrazine.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Safrazine.Approved, Investigational
RosiglitazoneSafrazine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineThe metabolism of Rotigotine can be decreased when combined with Safrazine.Approved
SalbutamolThe risk or severity of adverse effects can be increased when Safrazine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Salmeterol.Approved
SaprisartanSafrazine may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinSafrazine may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of Safrazine.Approved, Investigational, Vet Approved
SelexipagSafrazine may increase the hypotensive activities of Selexipag.Approved
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Safrazine.Approved
SitagliptinSafrazine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanSafrazine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilSafrazine may increase the hypotensive activities of Spirapril.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Safrazine.Approved, Investigational
SulfadiazineSafrazine may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleSafrazine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleSafrazine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Safrazine.Approved, Investigational
SunitinibSafrazine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololSafrazine may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Safrazine.Approved
TelmisartanSafrazine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilSafrazine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Safrazine is combined with Terbutaline.Approved
TerlipressinSafrazine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Tetrabenazine.Approved, Investigational
TetrahydrocannabivarinThe metabolism of Tetrahydrocannabivarin can be decreased when combined with Safrazine.Investigational
TetrahydropalmatineSafrazine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineSafrazine may increase the hypertensive activities of Tetryzoline.Approved
TheodrenalineSafrazine may increase the hypotensive activities of Theodrenaline.Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Safrazine.Approved, Investigational
TiboloneSafrazine may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenSafrazine may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Safrazine.Experimental
TimololSafrazine may increase the hypotensive activities of Timolol.Approved
TolazamideSafrazine may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineSafrazine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideSafrazine may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Safrazine.Approved, Withdrawn
TolonidineSafrazine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Safrazine.Approved
TorasemideSafrazine may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Safrazine.Approved, Investigational
TrandolaprilSafrazine may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineTranylcypromine may increase the hypertensive activities of Safrazine.Approved, Investigational
TravoprostSafrazine may increase the hypotensive activities of Travoprost.Approved
TrazodoneSafrazine may increase the serotonergic activities of Trazodone.Approved, Investigational
TreprostinilSafrazine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideSafrazine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinSafrazine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanSafrazine may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineSafrazine may increase the serotonergic activities of Trimipramine.Approved
UnoprostoneSafrazine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilSafrazine may increase the hypotensive activities of Urapidil.Investigational
ValsartanSafrazine may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Safrazine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Safrazine.Approved
VincamineSafrazine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineSafrazine may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Safrazine.Approved, Investigational
XipamideSafrazine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineSafrazine may increase the hypertensive activities of Xylometazoline.Approved, Investigational
ZimelidineThe risk or severity of adverse effects can be increased when Zimelidine is combined with Safrazine.Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Safrazine.Approved
ZofenoprilSafrazine may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Safrazine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
34042
PubChem Substance
310265156
ChemSpider
31375
ChEMBL
CHEMBL3301845
Wikipedia
Safrazine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.24 mg/mLALOGPS
logP1.51ALOGPS
logP1.69ChemAxon
logS-2ALOGPS
pKa (Strongest Basic)5.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area56.51 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity69.05 m3·mol-1ChemAxon
Polarizability23.14 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzodioxoles. These are organic compounds containing a benzene ring fused to either isomers of dioxole. Dioxole is a five-membered unsaturated ring of two oxygen atoms and three carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodioxoles
Sub Class
Not Available
Direct Parent
Benzodioxoles
Alternative Parents
Benzenoids / Oxacyclic compounds / Alkylhydrazines / Acetals / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Benzodioxole / Benzenoid / Alkylhydrazine / Oxacycle / Acetal / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Organooxygen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 23, 2015 22:19 / Updated on June 02, 2018 08:18